Catalyst

Slingshot members are tracking this event:

Phase 1/2 presentation of Jazz Pharma's (JAZZ) CPX-351 in Acute myeloid leukemia expected at ASCO May 31, 2019, 3:45 p.m. CT

Source Link:
http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-new-data-upcoming-asco-annual

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JAZZ Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jun 01, 2019
Occurred Source:
https://www.healio.com/hematology-oncology/leukemia/news/online/%7B1566b0f1-cb7a-450b-b67d-fe3cc84d84a7%7D/cpx-351-regimen-induces-high-response-rates-in-pediatric-relapsed-acute-myeloid-leukemia
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Cpx-351, Asco 2019, Acute Myeloid Leukemia, Aml
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.